Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
NCT ID NCT07689240
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This phase III trial compares the immunotherapy drug pembrolizumab to active surveillance (no treatment) after kidney cancer surgery in patients with non-clear cell renal cell carcinoma, a less common type of kidney cancer. The goal is to see if pembrolizumab can help the immune system attack any remaining cancer cells and delay the cancer from coming back. Participants will be randomly assigned to receive pembrolizumab or undergo regular monitoring, and researchers will track how long they remain cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab
- What this could lead to
- If it works, this could offer a new treatment option to delay cancer recurrence after surgery for a less common type of kidney cancer.
- What could go wrong
- This is an early-stage trial, and the drug may not improve outcomes or could cause side effects like immune-related inflammation. The benefit over surveillance alone is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Wheat germ supplement studied for immune boost in advanced cancer
- Gene test may guide kidney cancer therapy choice
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Could a probiotic boost a cancer drug? new trial tests the combo